This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Excluding special items, third-quarter adjusted net earnings from continuing operations were $0.06 per diluted share, compared to adjusted net earnings of $0.12 per diluted share during the same period last year.
Net earnings from continuing operations, excluding special items, for the nine months ended September 30, 2012 and 2011, were $0.25 per diluted share and $0.27 per diluted share, respectively.
During 2012, the Company completed the sale of its premium Print & Color brands, inventory and select equipment, and the permanent closure and sale of its Brokaw, Wisconsin, manufacturing site. The Company began reporting the operations of the Brokaw manufacturing facility and related closure activities as a discontinued operation as of March 31, 2012, in the condensed consolidated balance sheet. Additionally, the discontinued operation is separately presented from continuing operations for all periods presented in the condensed consolidated statements of operations. All results discussed below exclude the discontinued operation unless otherwise indicated.
Third-quarter net loss from continuing operations was $5.2 million, or $0.10 per share compared to net earnings of $5.4 million, or $0.11 per diluted share a year ago. On a year-over-year basis, consolidated net sales decreased five percent to $202 million with shipments measured in tons decreasing three percent. Year-to-date, the Company reported a net loss from continuing operations of $1.5 million, or $0.03 per share, compared with net earnings of $10.0 million, or $0.20 per diluted share in the comparable 2011 period. For the nine months ended September 30, consolidated net sales increased two percent to $631 million as shipments increased four percent.
On an adjusted basis, third-quarter results included after-tax expenses of $7.6 million, or $0.15 per diluted share related to settlement charges on certain defined benefit pension plans and $1.2 million, or $0.02 per diluted share for capital-related expense for the Tissue expansion project. Prior-year third-quarter results included after-tax capital-related expenses of $0.4 million, or $0.01 per diluted share for the Tissue expansion project.